09-10-2019
Paul Brady Photography / Shutterstock.com
California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
California, pay-for-delay, anticompetitive, antitrust, FTC, patent settlements, generics, market control, Governor Gavin Newsom
Par avoids pay-for-delay suit after court accepts payment was ‘fair’
10-03-2020
California pay-for-delay ban upheld during appeal, rules Ninth Circuit
25-02-2020
California mulls state generics brand
13-01-2020
Generics makers appeal pay-for-delay ban to Ninth Circuit
03-01-2020
FDA announces record generic approvals in 2019
21-10-2019
Teva to pay California $69m over pay-for-delay deals
30-07-2019
‘Considerable increase’ in pay-for-delay settlements: FTC report
24-05-2019
